Clinical Trial Search

Primary: Objective Response for HER2+ Patients (Best Objective Response a Patient Has Ever Experienced on Study) — 3; 13; 10; 11 Participants

Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…

Primary: Pathologic Complete Response (pCR) — 27 participants

Primary: Percentage of Subjects Able to Complete > 85% of the Planned Dose on Schedule — 60 percentage of participants

Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…

Primary: Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery — 56 percentage of…

Primary: Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and…

Primary: Percent Change in Proliferation as Measured by Ki-67

Primary: Pathological Complete Response After Preoperative Therapy With Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in Patients With HER-2 Positive Early Breast…

Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants

Primary: Overall Response Rate (ORR) — 30 percentage of participants

Primary: Objective Response Rate (ORR) — 30.8; 31.0; 55.6 percentage of participants

Primary: Percentage of Patients Who Complete Planned Oncologic Therapy Without the Development of a Cardiac Event or Asymptomatic Worsening of Cardiac Function. — 27 Participants

Primary: Pathological Complete Response Rates at Surgery — 16; 2 participants

Primary: Number of Participants With Tumor Response (Stable Disease) — 5 participants

Primary: Dose-Limiting Toxicity (DLT) of MK-3475 in Combination With Trastuzumab — 0; 0 Participants

Primary: Number Participants With Neutropenia, Graded According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4.03 — 2…

Primary: Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) — 3; 3; 15; 15 Participants

Primary: Cardiac Saftey — 68; 67; 66; 65 percentage of LVEF

Primary: Treatment-emergent Adverse Events Following Treatment With DS-8201a (Trastuzumab Deruxtecan) — 12; 12; 7; 6 Participants

Primary: Clinical Response — 3; 30; 11; 3 participants

Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010

Primary: Part I: Progression Free Survival (PFS) by Biomarker — NA; NA; 13.963; 1.216 months

Primary: Percent of Patients Who Achieve a pCR — 19; 2; 0; 0 Participants

Primary: Percentage of Participants With Immunohistochemical (IHC) Evaluation Between Site A and Others (Sites B, C, D and E) — 16.7; 12.5; 0.0; 8.3 percentage of participants

Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants

Primary: Invasive Disease-free Survival (DFS) — 42; 47 Participants

Primary: Objective Response Rate Per Composite Response Criteria — 7.5; 48.6; 33.3 percent of participants

Primary: Number of Patients Who Completed All Planned Therapy — 45 participants

Primary: Proportion of Patients Experiencing Grade 3 or 4 Diarrhea as Measured by NCI CTCAE v3.0 — 43 percentage of patients